Aim: To determine the therapeutic effect of thymosin β4 (Tβ4) for treatment of ischemic limb disease in a mouse model. Methods: A mouse model of hindlimb ischemia was created by permanent ligation of femoral arteries and internal iliac artery. Tβ4 was dissolved in sterile saline and intramuscularly injected into the centre and periphery of ligation area in the treatment group (n = 10) starting from the surgery day until 4 weeks after surgery, while control animals received saline injection only (n = 9). All animals were sacrificed at 6 weeks after surgery and used for immunohistochemistry studies. Results: Tβ4 stimulated angiogenesis was evidenced by increased vascular density based on CD31 immunostaining, which was signifycantly increased in Tβ4 group (562.5 ± 78.4/mm 2 ) as compared with control group (371.1 ± 125.7/mm 2 ; p < 0.05). The arteriole density based on CD31 and SMA dual immunostaining was similar between the Tβ4 (27.2 ± 16.9/mm 2 ) and control (35.3 ± 6/mm 2 ; p > 0.05) groups. Tβ4 increased Pax3/7 + skeletal muscle progenitor cell density. Pax3/7 + cell density of Tβ4 group (13.7% ± 2%) was significantly higher than that of the control group (4.3% ± 1.6%, p < 0.05). However, the numbers of central nuclei fiber and central nuclei per fiber were insignificantly increased in Tβ4 group as compared to control group. The numbers of central nuclei fiber were 8.9 ± 2.1 and 9.5 ± 1.6, and the central nuclei per fiber were 0.25 ± 0.07 and 0.48 ± 0.09 for control and Tβ4 groups, respectively. Conclusions: This preliminary study suggests that localized delivery of Tβ4 increased angiogenesis and skeletal muscle progenitor cell density in ischemic skeletal muscle, but failed to promote skeletal muscle regeneration.
INTRODUCTION
Thymosin β4 (Tβ4), a ubiquitous 43 amino acid, is a 5 kDa polypeptide that plays an important role in mediating cell survival, migration, and proliferation [1] . It is the most abundant member of the β-thymosin family in mammalian tissue and is regarded as the main G-actin sequestering peptide [1] . The role of Tβ4 in promoting cell survival, migration and proliferation has been extensively studied [2] [3] [4] . For instance, Tβ4 promotes cardiac cell survival, migration and proliferation after an episode of myocardial infarction Tβ4 induces hair follicle stem cell migration that contributes to new hair growth [2] [3] [4] . It promotes neuron survival and neurite outgrowth of cultured spinal cord neurons [3] .
In addition, Tβ4 has wound-healing and tissue-repair properties, which is associated with its ability to inhibit apoptosis and inflammation [5] [6] [7] [8] . It can promote dermal healing in normal animals as well as in impaired models of dermal wound healing, including aged mice, diabetic mice, and steroid-treated rats [5] . It promotes corneal wound healing by topical treatment after an alkali injury [6] . Tβ4 inhibits polymorphonuclear leukocyte infiltration and suppresses the expression of interleukin proteins (IL-lβ and IL-8), chemokines, macrophage inflammatory protein (MIP-1α, MIP-1β, and MIP-2), and monocyte chemoattractant protein-1 (MCP-1) in corneal wound healing after an injury [7, 8] . The anti-apoptotic properties displayed by Tβ4 is mediated by activating integrin-linked kinase (ILK), which results in activation of the survival kinase, Akt (also known as protein kinase B) [2] .
Studies have shown that Tβ4 is up-regulated in regenerating muscle fibers after an injury [9] . Our previous study demonstrated that Tβ4 increased human skeletal myoblast (hSkM) migration, proliferation, and decreased cell injury under hypoxia [10] . The protective effect is associated with increased activities of PI3K and AKT, and reduced activities of caspase-3 and -8. The current study aims to investigate the therapeutic effects of Tβ4 for treatment of hind limb ischemia. This preliminary study suggests that localized delivery of Tβ4 increased angiogenesis, and increased skeletal muscle progenitor cell density in ischemic skeletal muscle, but failed to promote skeletal muscle regeneration.
METHODS

Experimental Animal
All animals were handled in compliance with the Guide for the Care and Use of Laboratory Animals approved by the Institutional Animal Care and Use Committee at the National University of Singapore (NUS), Singapore. All animals were maintained by research animal resource (RAR) of NUS.
Eight-week old female Balb/C mice were purchased from the Centre for Animal Resources of NUS and were housed in vented cage system with a 12 hour light-dark cycle and received standard mouse chow. Balb/c mouse is a laboratory-bred strain of the house mouse and is one of the most widely used inbred strains used in animal experimentation. Mouse hind limb ischemia model was produced in 19 Balb/C mice (18 -20 grams body weight) by permanent ligation of femoral artery [11] . Briefly, the superficial and deep femoral arteries and internal iliac artery of the right hind limb were exposed and ligated from the inguinal ligament with the animal under anesthesia. Multiple ligatures of the artery beginning from the inguinal ligament down to the point where it bifurcates into the popliteal and saphenous arteries were closed with 8-0 nylon sutures. The superficial femoral artery was sectioned near and distal to the inguinal ligament between two suture ligations. The deep femoral artery was cauterized distal to its ligation site. Wounds were closed, and the animals were allowed to recover. All animals received antibiotics and painkiller post-surgery to prevent infection and relieve pain.
Tβ4 Injection
Tβ4 was dissolved in sterile saline to a concentration of 2 µg/mL. Starting from the surgery day, 0.1 mL saline with Tβ4 was injected intramuscularly into the centre and periphery of femoral artery ligation area in the treatment group (n = 10), while control animals received 0.1 mL saline injection (n = 9). All animals received daily injection until 4 weeks after surgery. Then animals were sacrificed at 6 weeks after treatment and used for immunohistochemistry studies. No injection was made during the last two weeks. The aim of the additional two weeks was to exclude the immune reactions associated with injection, which may compromise the immunohistochemistry study of skeletal muscle.
Histochemical and Immunohistochemical Studies
Mouse medial thigh muscle was explanted. Cryo-sections of 6 µm thickness were cut and used for fluorescence immunostaining. To quantify the muscle fibers with central nuclei, tissue sections were fluorescence immunostained with rabbit anti-dystrophin (Santa Cruz Biotech, USA) and 4,6-diamidino-2-phenylindole (DAPI, Sigma Aldrich, USA). To quantify the undifferentiated skeletal muscle progenitor cells, mouse tissue sections were dual immunostained with goat anti-Pax3/7 (Santa Cruz Biotech, USA) and rabbit anti-dystrophin. Eight non-over-laping microscopic fields/muscle (n= 5 animal each group) were calculated in control and Tβ4 group muscle sections.
Vascular Density Quantification
Dual fluorescence immunostaining for CD31 (Santa Cruz Biotech, USA) and smooth muscle actin (SMA) (Sigma Aldrich, USA) was carried out to quantify vascular density at 6 weeks after treatment. For each tissue section, the number of blood vessels was counted from 4 -8 randomly selected microscopic fields at 200× magnification. A total of 25 tissue sections from five animals per group were used to measure the final average vascular density.
Statistical Analysis
All data are expressed as mean ±SED. All statistical analyses were performed with SPSS (version 17). The difference between groups was analyzed by the method of student t-test. All tests were performed with a significance level of 5%.
RESULTS
Body Weight and Clinical Outcome
There was no significant change of body weight between groups: they were 18.7 ± 0.4 g and 19 ± 0.4 g of control and Tβ4 group animals before treatment, respectively and increased to 19.6 ± 0.5 g and 19.2 ± 0.3 g after treatment. All mice survived the experiments. However, two mice in Tβ4 group each had one nail fall off from the ischemic limb.
Evidence for Neovascularization
0.25 ± 0.07 and 0.48 ± 0.09 for control and Tβ4 groups, respectively. This suggests that Tβ4 did not increase skeletal muscle regeneration. The vascular density based on CD31 immunostaining was significantly increased in Tβ4 group (562.5± 78.4/mm 2 ) as compared with control group (371.1 ± 125.7/mm 2 ; p < 0.05) at 6 weeks after treatment (Figures 1(A), (D) and (G) ). The arteriole density based on CD31 and SMA dual immunostaining was similar between the Tβ4 group (Tβ4 group=27.2 ± 16.9/mm 2 ) and control group (35.3 ± 6/mm 2 ; p>0.05) (Figures 1(B), (C),  (E), (F) and (H) ). This suggests that Tβ4 increases angiogenesis only.
Increased Pax3/7 + Skeletal Muscle Progenitor Cell Density
Immunostaining for Pax3/7 expression showed that Tβ4 significantly increased Pax3/7 + nuclei (13.7 ± 2%) of total nuclei as compared to control group (4.3 ± 1.6%) per high magnification field (p < 0.05) (Figure 3) . This suggests that Tβ4 increased the skeletal muscle progenitor cell density in ischemic skeletal muscle.
Skeletal Muscle Histology
DISCUSSION
Skeletal muscle histology demonstrated that Tβ4 insignificantly increased number of central nucleated fiber and central nuclei per fiber compared to control mouse (Figure 2) . The numbers of central nuclei fiber were 8.9 ± 2.1 and 9.5 ± 1.6, and the central nuclei per fiber were
The current preliminary study demonstrates that Tβ4 increased angiogenesis and skeletal muscle progenitor cell density, but failed to promote skeletal muscle regeneration in ischemic skeletal muscle. Tβ4 is the most abundant member of the β-thymosin family in mammalian tissue [1] . It is regarded as an intracellular monomeric G-actin sequestering peptide and inhibits the assembly of actin fibres within cells [1] . Besides, Tβ4 has been shown to play an important role in mediating cell migration, proliferation, and survival [2, 3, 10] . It promotes epicardial progenitor cells differentiation into endothelial cells for coronary vasculogenesis and angiogenesis [12] . Tβ4 reduces cardiomyocyte injury after myocardial infarction and promotes cardiac cell migration and proliferation [2] . It enhances endothelial cell migration and adhesion [13] [14] [15] . Thus, Tβ4 has been shown to promote tissue regeneration [14] [15] [16] .
OPEN ACCESS
Our previous study demonstrated that Tβ4 increased human skeletal myoblast (hSkM) migration, proliferation, and decreased cell injury under hypoxia in vitro [10] . The current study further tested the beneficial effects of Tβ4 on neovascularization and muscle regeneration in a mouse model of ischemia limb disease. It was found that Tβ4 significantly increased capillary density. This is associated with its biological function on endothelial cells: promoting endothelial cell migration and proliferation. Malinda et al., [13] demonstrated that Tβ4 has chemoattractive activity and promotes angiogenesis by stimulating the migration of endothelial cells in vitro and in vivo as well. Grant et al. [15] showed that Tβ4 not only increased tubular structure formation of HUVECs in vitro, but also enhanced vascular sprouting in the coronary artery ring angiogenesis assay. Qiu et al. [16] found that Tβ4 induced endothelial cell migration through the PI3K/Akt/eNOS signal pathway. Current study is consistent with these studies. It was found that Tβ4 administration increased capillary density by 50% as compared with control animal based on CD31 expression. However, no significant increase of arteriole density was noted. Thus, Tβ4 stimulates angiogenesis but not arteriogenesis in mouse ischemic limb.
Significantly increased Pax3/7 expressing nuclei were found in Tβ4 treated skeletal muscle. This indicates that Tβ4 increased Pax3/7 expressing progenitor cell density in ischemic limb muscle. Recent studies have identified Pax3 + /Pax7 + somatic cells as the source of muscle progenitors [17, 18] . Pax3 + /Pax7 + cells are the common progenitors responsible for all embryonic, fetal, and adult myogenesis in axial and limb muscles. Pax3 is sufficient to induce MyoD and Myf5 in vitro [19] . Pax7 is required for maintenance of adult satellite cells [20, 21] . In the current study, a significantly increased level of Pax3/7 + cells was found. Tβ4 may stimulate the proliferation of Pax3/7 + progenitor cells in ischemic area or enhance the migration of cells to ischemic muscle. Our previous study demonstrated that Tβ4 increased hSkM migration and proliferation in vitro. Thus, it's possible that Tβ4 increases Pax3/7 + progenitor cell proliferation and stimulates cell migration and homing to ischemic muscle. Though Pax3/7 progenitor cell density was increased, there is no significantly increased skeletal muscle regeneration between Tβ4 and control groups. The central nucleated fiber and the central nuclei per fiber of Tβ4 were insignificantly increased as compared with control group. This finding is inconsistent with Spurney's study [22] , which demonstrated that Mdx mice treated with Tβ4 showed a significant increase in skeletal muscle regenerating fibers compared to untreated Mdx mice. This might be related to animal model and dosage of Tβ4. Spurney's study used a chronic muscle degeneration animal model and injected Tβ4 twice per week for six months. The current study adopted an acute ischemic model and daily injected Tβ4 for four weeks. The different pathophysiological condition of skeletal muscle may have a different response to Tβ4. A much higher dose of Tβ4 was used in Spurney's study also. This may stimulate the fusion of skeletal muscle progenitor cells, which in turn contributes to the muscle regeneration.
In summary, the current study demonstrates that Tβ4 stimulates angiogenesis and increased skeletal muscle progenitor cell density, but failed to increase regenerating muscle fiber in ischemic limb muscle. Further study should be performed to investigate the underlying mechanism that the role of Tβ4 on homing and migrating of Pax3/7 + muscle progenitor cells has.
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